ABSTRACT
Objective:To detect and analyze the infections of respiratory pathogens in patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD).Methods:Through retrospective analysis, 335 AECOPD patients hospitalized from October 2016 to September 2018 in the First People′s Hospital of Pinghu were selected.The indirect immunofluorescence method was used to detect IgM antibody of eight kinds of respiratory pathogens, and the results were analyzed.Results:The positive rate of respiratory pathogens-IgM antibody in patients with AECOPD was 29.9%.There were 57 cases with one single pathogen infection, 36 cases with two pathogens mixed infection, 7 cases with three kinds of pathogens mixed infection.The influenza virus B [52.0%(78/150)] was the most common, followed by influenza virus A [27.3%(41/150)], the positive rates of pathogens were influenza virus B>influenza virus A>respiratory syncytial virus>parainfluenza virus>Legionella pneumophila>Mycoplasma pneumoniae>Chlamydia pneumoniae>adenovirus.There was no statistically significant difference in different age groups(χ 2=0.047, P=0.829). The positive rates of pathogens-IgM in spring[55.3%(63/114)] and winter[58.1%(54/93)] were higher than those in summer[26.2%(16/61)] and autumn[25.4%(17/67)], the differences were statistically significant(χ 2=30.398, P<0.01). Conclusion:AECOPD is closely related with respiratory pathogens, especially influenza virus.We should do preventive work well in epidemic season.
ABSTRACT
Objective To study the application of BNP,NT-proBNP and ST2 in diagnosis of heart failure (HF).Methods Ninety-seven HF patients admitted to our hospital served as a HF group and 61 HF-free patients served as a control group.The patients in HF group were further divided in to class Ⅱ group (n=32),class Ⅲ group (n=36) and class Ⅳ group (n=29) according to their cardiac function in NYHA classification.The serum ST2,BNP and NT-proBNP levels were measured and their value in diagnosis of HF was analyzed.Results The serum BNP,NT-proBNP and ST2 levels were significantly higher in HF group than in control group (396.0 ng/L vs 39.4 ng/L,P＜0.01;1825.0 ng/L vs 215.0 ng/L,P＜0.01;56.8 μg/L vs 25.4 μg/L,P＜0.01),which increased with the increasing cardiac function in NYHA classification (P＜0.01).The area under the ROC curve for BNP,NT-proBNP,ST2,combined NT-proBNP and ST2 was 0.874,0.891,0.842,0.905 respectively for the diagnosis of HF.Conclusion BNP,NT-proBNP and ST2,3 new biomarkers,can improve the diagnosis of HF.
ABSTRACT
Objective To investigate the effect of ectectin on the expression of EGFR gene 19 and 21 in patients with advanced lung cancer.Aim to provide scientific reference.Methods68 patients with advanced lung cancer were treated with 3 months of ectectin.Serum free DNA was extracted from patients before and after treatment.RT-PCR was performed to amplify EGFR exon 19 and exon 21, EGFR gene mutations were detected by gene sequencing, and the mutation status of exon 19 and exon 21 of EGFR gene before and after treatment were evaluated.ResultsIn 68 patients with lung cancer before and after treatment with ectatinib, Histopathological types were correlated with the efficacy of ectectin hydrochloride.DCR of adenocarcinoma was significantly higher than that of squamous cell carcinoma.18 cases of EGFR mutations, there is no CR and PD cases, PR 11 cases, SD 7 cases, ORR 61.1%, DCR 100%.In the remaining 50 patients with unknown EGFR status, PR 24, SD 4, PD 15, ORR 48.0%, DCR 56.0%.There was no significant difference in the mutation rate of exon 19 and 21 between before and after chemotherapy.The mutation status of serum EGFR was correlated with the pathological type of patients (P<0.02).The EGFR gene mutation rate was 35.4% (17/48) before chemotherapy and 50% after chemotherapy.The rate of EGFR gene mutation was 55% before and after chemotherapy.ConclusionEctectin is effective in the treatment of advanced lung cancer, and it is effective in lung adenocarcinoma and may lead to the change of serum EGFR gene mutation in lung cancer patients,for the first-line application of patients treated with ectectin hydrochloride should always observe the changes in serum EGFR gene, to avoid blindness in treatment of patients.